CORONA

Corona Remedies Share Price

 

 

Start SIP in CORONA

Start SIP
Corona Remedies live price: ₹1499.2. It opened at ₹1,541 vs previous close ₹1,541; intraday high/low: ₹1,568/₹1,486. The 50 DMA stands at ₹1,536.41.

Corona Remedies Performance

  • Today's Low
  • ₹1,486
  • Today's High
  • ₹1,568
  • 52 Week Low
  • ₹1,337
  • 52 Week High
  • ₹1,699
  • Open Price₹1,541
  • Previous Close₹1,541
  • Volume30,605
  • 50 DMA₹1,536.41
  • 100 DMA-
  • 200 DMA-

Investment Returns

  • Over 1 Month -5.11%
  • Over 3 Month + 3.86%
  • Over 6 Month + 41.17%
  • Over 1 Year + 41.17%

Smart Investing Starts Here Start SIP with Corona Remedies for Steady Growth!

Invest Now

Corona Remedies Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -
  • PEG Ratio
  • -
  • Market Cap Cr
  • 9,169
  • P/B Ratio
  • 13.1
  • Average True Range
  • 64.06
  • EPS
  • 30.17
  • Dividend Yield
  • 0
  • MACD Signal
  • 9.22
  • RSI
  • 40.48
  • MFI
  • 39

Corona Remedies Financials

Corona Remedies Technicals

EMA & SMA

Current Price
₹1,499.20
-41.8 (-2.71%)
pointer
  • Bearish Moving Average 11
  • Bullish Moving Average 0
  • 20 Day
  • ₹1,569.98
  • 50 Day
  • ₹1,536.41
  • 100 Day
  • -
  • 200 Day
  • -

Resistance and Support

1517.57 Pivot Speed
  • R3 1,632.13
  • R2 1,600.07
  • R1 1,549.63
  • S1 1,467.13
  • S2 1,435.07
  • S3 1,384.63

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Corona Remedies Limited is a fast-growing Indian pharmaceutical company focused on women’s healthcare, cardio-diabeto, pain management, and urology. It operates two manufacturing facilities in Gujarat and Himachal Pradesh with 11 production lines and EU-GMP/WHO-GMP certifications.

Corona Remedies Ltd has an operating revenue of Rs. 2,246.51 Cr. on a trailing 12-month basis. An annual revenue growth of 18% is outstanding, Pre-tax margin of 17% is great, ROE of 24% is exceptional. The company has a reasonable debt to equity of 3%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and close to its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 82 which is a GOOD score indicating consistency in earnings, a RS Rating of 81 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 30 indicates it belongs to a strong industry group of Medical-Ethical Drugs and a Master Score of B is close to being the best. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Corona Remedies Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-02 Quarterly Results
2026-01-02 Quarterly Results Inter-alia, to consider and approve the financial results for the period ended September 30, 2025

Corona Remedies F&O

Corona Remedies Shareholding Pattern

69%
6.38%
0.34%
1.84%
0%
1.36%
21.08%

Corona Remedies FAQs

Corona Remedies share price is ₹1,499 As on 04 April, 2026 | 08:32

The Market Cap of Corona Remedies is ₹9169.1 Cr As on 04 April, 2026 | 08:32

The P/E ratio of Corona Remedies is As on 04 April, 2026 | 08:32

The PB ratio of Corona Remedies is 13.1 As on 04 April, 2026 | 08:32

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23